Your browser is no longer supported. Please, upgrade your browser.
AMGN Amgen Inc. weekly Stock Chart
Amgen Inc.
IndexS&P 500 P/E15.48 EPS (ttm)12.63 Insider Own0.20% Shs Outstand607.00M Perf Week-5.90%
Market Cap118.65B Forward P/E12.40 EPS next Y15.77 Insider Trans-2.09% Shs Float598.41M Perf Month-1.71%
Income7.96B PEG1.99 EPS next Q3.49 Inst Own79.20% Short Float1.63% Perf Quarter11.01%
Sales23.56B P/S5.04 EPS this Y14.80% Inst Trans-2.85% Short Ratio3.08 Perf Half Y2.21%
Book/sh17.78 P/B10.99 EPS next Y10.13% ROA12.40% Target Price214.84 Perf Year-2.02%
Cash/sh35.85 P/C5.45 EPS next 5Y7.77% ROE65.70% 52W Range166.30 - 211.90 Perf YTD0.41%
Dividend5.80 P/FCF21.20 EPS past 5Y13.70% ROI19.80% 52W High-8.41% Beta1.09
Dividend %2.97% Quick Ratio2.60 Sales past 5Y4.90% Gross Margin82.20% 52W Low16.70% ATR5.05
Employees21500 Current Ratio2.90 Sales Q/Q-3.10% Oper. Margin41.80% RSI (14)43.05 Volatility1.98% 2.00%
OptionableYes Debt/Eq2.84 EPS Q/Q2.70% Profit Margin33.80% Rel Volume0.43 Prev Close195.47
ShortableYes LT Debt/Eq2.58 EarningsOct 29 AMC Payout43.60% Avg Volume3.16M Price194.07
Recom2.30 SMA20-4.55% SMA501.39% SMA2003.48% Volume636,276 Change-0.71%
Aug-19-19Downgrade Mizuho Buy → Neutral $208 → $212
May-23-19Upgrade Citigroup Neutral → Buy
May-21-19Initiated Credit Suisse Outperform $208
Jan-28-19Downgrade Evercore ISI Outperform → In-line
Oct-01-18Initiated Cantor Fitzgerald Neutral $223
Apr-05-18Reiterated Barclays Equal Weight $190 → $180
Feb-12-18Reiterated Mizuho Buy $192 → $200
Jan-23-18Upgrade Argus Hold → Buy
Nov-01-17Downgrade Argus Buy → Hold
Oct-26-17Reiterated RBC Capital Mkts Sector Perform $192 → $188
Sep-28-17Reiterated Mizuho Buy $183 → $198
Sep-15-17Initiated RBC Capital Mkts Sector Perform $192
Jul-11-17Resumed Jefferies Buy
Jun-23-17Initiated Deutsche Bank Hold $172
Apr-05-17Downgrade Jefferies Buy → Hold
Mar-09-17Initiated UBS Neutral $185
Feb-01-17Upgrade BofA/Merrill Neutral → Buy
Dec-20-16Downgrade Credit Suisse Outperform → Neutral
Dec-13-16Initiated Oppenheimer Outperform
Nov-08-16Initiated Mizuho Buy $164
Sep-16-19 11:30AM  S&P 500 buybacks decline significantly in Q2 2019; expenditures still remain higher than the pre-2018 levels PR Newswire
08:48AM  Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study Zacks
Sep-13-19 04:00PM  Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference PR Newswire
11:08AM  Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland Zacks
10:30AM  Celgene's (CELG) Leukemia Candidate Meets Endpoints in Study Zacks
10:13AM  The Zacks Analyst Blog Highlights: Amgen, Cisco, Berkshire Hathaway, T. Rowe Price and McKesson Zacks
09:00AM  Amgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival PR Newswire
08:44AM  REGENXBIO (RGNX) Catches Eye: Stock Jumps 5.8% Zacks
08:00AM  Amgen Stock Is The Biggest Biotech Stock, But Should You Buy It? Investor's Business Daily
05:00AM  2019 BusinessWoman of the Year honoree: Jaclyn Schuler American City Business Journals
Sep-12-19 01:52PM  Top Research Reports for Amgen, Cisco & Berkshire Hathaway Zacks
10:13AM  Puma Biotech's sNDA for Nerlynx Combo Gets FDA Acceptance Zacks
09:00AM  Amgen Highlights New Data From KYPROLIS® (carfilzomib) And Oncology Pipeline At IMW 2019 PR Newswire
Sep-11-19 11:49AM  deCODE in Iceland Agrees to Sequence Half of UK Biobanks Participants CNW Group
11:37AM  Ultragenyx to Submit sBLA for Label Expansion of Crysvita Zacks
10:49AM  Biotech Stock Roundup: AMGN's Lung Cancer Candidate, ALXN's Deal With Eidos in Focus Zacks
Sep-10-19 04:13PM  Is Nancy Pelosi's Drug-Pricing Plan Feasible Or Is It A Political Ploy? Investor's Business Daily
11:39AM  Alexion (ALXN) In-licenses Amyloidosis Candidate In Japan Zacks
09:31AM  Company News For Sep 10, 2019 Zacks
09:01AM  Adaptimmune (ADAP) Gets Orphan Drug Status for T-cell Therapy Zacks
07:59AM  Horizon's (HZNP) Eye Disease Drug Gets FDA's Priority Review Zacks
06:55AM  Amgen Falls 3%
Sep-09-19 04:24PM  Amgen Stock Dives On Lackluster Cancer Test But There's A Bright Side Investor's Business Daily
01:38PM  US STOCKS-Tech, healthcare weigh on Wall Street, stimulus hopes flicker Reuters
12:17PM  [video]Dow Finishes Higher; Wall Street Wavers Amid Expected Central Bank Stimulus
11:21AM  Novartis Announces Positive Long-Term Data on Migraine Drug Zacks
10:27AM  Amgen's KRAS Inhibitor Shows Lukewarm Response In Lung Cancer Study Benzinga
10:26AM  [video]Eli Lilly's Must-Hold Level on Drug-Data Pullback
10:10AM  Amgen's KRAS Inhibitor Shows Response in Larger NSCLC Group Zacks
08:59AM  Amgen Stock Is Falling as Cancer-Drug Report Fails to Impress Investors
08:17AM  Could Small Drug Trial Hold Big Potential for Amgen?
06:22AM  [video]Amgen Shares Tumble After Lung Cancer Treatment Update Misses Forecasts
05:41AM  Amgen's Lower Open Tests Support but the Bigger Picture Is More Important
05:34AM  Amgen Falls 3%
Sep-08-19 11:07PM  Amgen/cancer drugs: Seal of approval Financial Times
09:00AM  Better Buy: Amgen vs. Celgene Motley Fool
03:45AM  Amgen drug shrinks lung cancer tumors in half of patients -study Reuters
03:45AM  Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Larger Patient Group At WCLC 2019 PR Newswire
Sep-06-19 04:48PM  Bad News Keeps Piling Up For Alexion's Soliris But Shares Just Rallied Investor's Business Daily
03:06PM  Why Amgen's Spending Billions to Buy This 1 Drug; Plus Heart Disease Has a New Enemy Motley Fool
09:23AM  Can Copycats Take On $198 Billion In Blockbuster Biotech Sales? Investor's Business Daily
06:32AM  Meet Jaclyn Schuler, a 2019 BusinessWoman of the Year honoree American City Business Journals
Sep-05-19 09:16PM  4 Biotech Stocks With Big Catalysts in September Motley Fool
04:00PM  Amgen To Present At The Morgan Stanley Global Healthcare Conference PR Newswire
10:08AM  Here's Why Alexion Pharmaceuticals Dropped 11% in August Motley Fool
09:36AM  Merck's Keytruda Combination Gets EC Nod for Kidney Cancer Zacks
09:15AM  How Boulder biotech companies are putting Colorado on the gene-editing map American City Business Journals
06:50AM  Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar? Zacks
Sep-04-19 04:00PM  Amgen To Webcast Investor Call At IASLC 2019 World Conference on Lung Cancer PR Newswire
02:43PM  Trying to turn 'natural killers' against cancer, Peninsula drug maker raises $114 million American City Business Journals
01:01PM  5 Companies Hit 52-Week Highs
10:02AM  Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More Zacks
09:39AM  Roche Extends Offer to Acquire Spark Therapeutics Yet Again Zacks
09:15AM  Amgens White Whale Cancer Data May Send Shares to Record High Bloomberg
Sep-03-19 05:46PM  Top-Performing Biotech ETFs YTD Zacks
08:00AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
Sep-02-19 03:13PM  The Week Ahead In Biotech: Cardiology, Analyst Conferences In The Spotlight Benzinga
Aug-30-19 04:33PM  How Amgen Could Take A Hammer To Sales Of Alexion's Biggest Drug Investor's Business Daily
11:33AM  Amgen drug patent challenge slices $2B off Alexion's market cap American City Business Journals
06:48AM  Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar? Zacks
Aug-29-19 11:24AM  Roche's Tecentriq Combo Gets EU Nod for Critical Breast Cancer Zacks
09:31AM  Amgen (AMGN) Up 11.2% Since Last Earnings Report: Can It Continue? Zacks
09:30AM  Is Amgen (AMGN) Outperforming Other Medical Stocks This Year? Zacks
09:24AM  Amgens Purchase of Otezla Is Now Being Seen as a Solid Strategic Fit
09:16AM  Regeneron-Sanofi Get Favorable Ruling Against Amgen in Court Zacks
08:24AM  What Kind Of Shareholder Owns Most Amgen Inc. (NASDAQ:AMGN) Stock? Simply Wall St.
07:39AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
07:38AM  The Daily Biotech Pulse: EC Approves Roche's Tecentriq For Breast Cancer, Trevena On Track For NDA Resubmission, Edap Earnings Benzinga
Aug-28-19 06:55PM  What Investors Need to Know About the Celgene, Amgen & Bristol-Myers Deals Zacks
04:18PM  U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight Reuters
03:41PM  UPDATE 3-U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight Reuters
01:31PM  3 Top Biotech Stocks to Buy Right Now Motley Fool
10:43AM  Amgen Faces Trouble in the Anti-Cholesterol-Drug Battle, Analyst Says
10:34AM  Biotech Stock Roundup: AMGN to Buy CELG's Otezla, ALXN's Soliris Gets EC Nod & More Zacks
10:10AM  Here's Why Merck (MRK) is Outperforming Its Industry Of Late Zacks
09:15AM  Top Ranked Momentum Stocks to Buy for August 28th Zacks
09:00AM  New Amgen Data To Be Presented At ESC Congress 2019 Highlight Additional Evidence For Repatha® (Evolocumab) Effectiveness In Cardiovascular Disease Across Multiple Patient Groups PR Newswire
06:28AM  Alexion Wins EC Nod for Soliris in Nervous System Disorder Zacks
Aug-27-19 11:19AM  Medicines Company's Inclisiran Succeeds in Pivotal Study Zacks
11:01AM  4 Biotech Stocks to Buy That Are on the Move InvestorPlace
10:55AM  Amgen to Buy Celgene's Otezla for $13.4B: Is it a Good Buy? Zacks
10:18AM  Amgen Paid Too Much for Otezla. Why One Analyst Says It Was the Right Thing to Do.
10:07AM  Company News for Aug 27, 2019 Zacks
10:05AM  Amgen to Buy Celgene's Otezla: 5 ETF Drugs Zacks
08:58AM  Alexion (ALXN) Down 3.2% After Amgen Buys Otezla From Celgene Zacks
08:05AM  Bristol-Myers Announces Sale of Celgene's Otezla to Amgen Zacks
06:46AM  Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar? Zacks
12:00AM  Amgen adds Otezla to its medicine cabinet Financial Times
Aug-26-19 05:06PM  What Happened in the Stock Market Today Motley Fool
04:32PM  Celgene's $13.4 Billion Deal With Amgen Is a Win-Win-Win Motley Fool
04:31PM  Amgen Inc. -- Moody's: Amgen's Otezla acquisition brings high-growth asset but at a rich price Moody's
04:15PM  Why Amgen's $13.4 Billion Otezla Buy Is A Boon For These Biotechs Investor's Business Daily
03:32PM  5 Top Stock Trades for Tuesday: NFLX, AMGN, ACB, BMY InvestorPlace
01:53PM  Celgene News: CELG Stock Jumps on Sale of Otezla to Amgen InvestorPlace
01:21PM  Amgen's Proposed $13.4B Acquisition Of Celgene's Otezla: What You Need To Know Benzinga
12:53PM  Amgen stock pops after company agrees to buy Celgenes blockbuster anti-inflammatory drug Otezla MarketWatch
12:52PM  The Dow Is Up Because Markets Want to Believe the Trade War Can End
12:50PM  Jim Cramer: Why It Doesn't Matter How Much Amgen Paid for Otzela
11:23AM  Jim Cramer Weighs In on Amgen's Deal, Salesforce and U.S.-China Trade War
10:57AM  Amgen Will Buy Celgene Drug in $13.4 Billion Antitrust Sale Bloomberg
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells. It also markets other products in various markets, including Kyprolis, Nplate, Vectibix, Repatha, NEUPOGEN, Parsabiv, Blincyto, Aimovig, Imlygic, Corlanor, Kanjintitm, and Amgevitatm. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaborative agreements with Novartis; UCB; Bayer HealthCare Pharmaceuticals Inc.; Syapse; and DaVita Inc., as well as strategic research partnership with the University of Washington's Institute for Protein Design. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SUGAR RONALD DDirectorSep 04Option Exercise54.712,000109,42016,336Sep 04 06:08 PM
SUGAR RONALD DDirectorSep 04Sale206.702,000413,40014,336Sep 04 06:08 PM
Patton Cynthia MSVP & CCOAug 30Option Exercise158.438,6241,366,33132,648Sep 04 06:07 PM
Patton Cynthia MSVP & CCOAug 30Sale208.0713,4262,793,51022,097Sep 04 06:07 PM
SUGAR RONALD DDirectorAug 07Option Exercise54.712,000109,42016,336Aug 08 07:09 PM
Williams R SandersDirectorAug 07Sale183.0442577,7925,838Aug 08 07:12 PM
SUGAR RONALD DDirectorAug 07Sale183.042,000366,08014,336Aug 08 07:09 PM
SUGAR RONALD DDirectorJul 03Option Exercise54.712,000109,42016,336Jul 08 04:23 PM
SUGAR RONALD DDirectorJul 03Sale187.582,000375,16014,336Jul 08 04:23 PM
SUGAR RONALD DDirectorJun 05Option Exercise54.712,000109,42016,219Jun 05 06:55 PM
SUGAR RONALD DDirectorJun 05Sale175.682,000351,36014,219Jun 05 06:55 PM
SUGAR RONALD DDirectorMay 01Option Exercise54.712,000109,42015,092May 03 05:37 PM
SUGAR RONALD DDirectorMay 01Sale175.732,000351,46013,092May 03 05:37 PM
SUGAR RONALD DDirectorApr 03Option Exercise54.712,000109,42015,092Apr 03 06:27 PM
SUGAR RONALD DDirectorApr 03Sale193.182,000386,36013,092Apr 03 06:27 PM
SUGAR RONALD DDirectorMar 06Option Exercise54.712,000109,42014,988Mar 08 07:47 PM
SUGAR RONALD DDirectorMar 06Sale188.882,000377,76012,988Mar 08 07:47 PM
SUGAR RONALD DDirectorFeb 07Option Exercise54.712,000109,42014,988Feb 11 09:27 PM
SUGAR RONALD DDirectorFeb 07Sale190.002,000380,00012,988Feb 11 09:27 PM
Jacks TylerDirectorDec 06Option Exercise82.6020,0001,652,00028,979Dec 10 08:46 PM
Jacks TylerDirectorDec 06Sale195.4120,0003,908,2328,979Dec 10 08:46 PM
Piacquad DavidSVP, Business DevelopmentNov 30Option Exercise54.696,500355,48545,128Dec 03 08:13 PM
Patton Cynthia MSVP & CCONov 29Option Exercise54.691,77797,18423,090Dec 03 08:11 PM
Patton Cynthia MSVP & CCONov 29Sale202.881,777360,52021,313Dec 03 08:11 PM